Fig. 4.

Immunogenicity of HLA-presented peptides.

Expanded PBMCs from 4 HBV resolvers and 2 patients with HBV/HCC were restimulated with peptides derived from (A) HBV or tumour (B) antigens. IFNγ concentrations were measured using ELISA and corrected for background (vehicle). Grey boxes present the number of responsive donors (background corrected mean ≥ mean + 3 × SD of vehicle) vs. subjects tested. HCC, hepatocellular carcinoma; HLA, human leucocyte antigen; IFNγ, interferon γ PBMC, peripheral blood mononuclear cell; PHA, phytohemagglutinin; Pol, polymerase; TAA, tumour-associated antigens.